Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 315

The DOI matches its Crossref record; 467 of the 467 references it cites were found in a registry or an index.

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials

Open access
Weiner, Michael W., Veitch, Dallas P., Aisen, Paul S., Beckett, Laurel A., Cairns, Nigel J., Green, Robert C., Harvey, Danielle, Jack, Clifford R., Jagust, William, Morris, John C., Petersen, Ronald C., Saykin, Andrew J., Shaw, Leslie M., Toga, Arthur W., Trojanowski, John Q., Alzheimer's Disease Neuroimaging Initiative·2017·Alzheimer's & Dementia

Abstract

Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers. This review summarizes the over 400 publications using ADNI data during 2014 and 2015. Methods: We used standard searches to find publications using ADNI data. Results: (1) Structural and functional changes, including subtle changes to hippocampal shape and texture, atrophy in areas outside of hippocampus, and disruption to functional networks, are detectable in presymptomatic subjects before hippocampal atrophy; (2) In subjects with abnormal β‐amyloid deposition (Aβ+), biomarkers become abnormal in the order predicted by the amyloid cascade hypothesis; (3) Cognitive decline is more closely linked to tau than Aβ deposition; (4) Cerebrovascular risk factors may interact with Aβ to increase white‐matter (WM) abnormalities which may accelerate Alzheimer's disease (AD) progression in conjunction with tau abnormalities; (5) Different patterns of atrophy are associated with impairment of memory and executive function and may underlie psychiatric symptoms; (6) Structural, functional, and metabolic network connectivities are disrupted as AD progresses. Models of prion‐like spreading of Aβ pathology along WM tracts predict known patterns of cortical Aβ deposition and declines in glucose metabolism; (7) New AD risk and protective gene loci have been identified using biologically informed approaches; (8) Cognitively normal and mild cognitive impairment (MCI) subjects are heterogeneous and include groups typified not only by “classic” AD pathology but also by normal biomarkers, accelerated decline, and suspected non‐Alzheimer's pathology; (9) Selection of subjects at risk of imminent decline on the basis of one or more pathologies improves the power of clinical trials; (10) Sensitivity of cognitive outcome measures to early changes in cognition has been improved and surrogate outcome measures using longitudinal structural magnetic resonance imaging may further reduce clinical trial cost and duration; (11) Advances in machine learning techniques such as neural networks have improved diagnostic and prognostic accuracy especially in challenges involving MCI subjects; and (12) Network connectivity measures and genetic variants show promise in multimodal classification and some classifiers using single modalities are rivaling multimodal classifiers. Discussion: Taken together, these studies fundamentally deepen our understanding of AD progression and its underlying genetic basis, which in turn informs and improves clinical trial design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2016.11.007

Cites

467 of 467 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 467 references

Research works printed but not linked: 21

  1. Alexander GE, 2016, A cognitive psychometric model for the psychodiagnostic assessment of memory‐related deficits, Psychol Assess, 28, 279, 10.1037/pas0000163 · doi:10.1037/pas0000163
  2. Tan M, 2015, Spectral Laplace‐Beltrami wavelets with applications in medical images, IEEE Trans Med Imaging, 34, 1005, 10.1109/TMI.2014.2363884 · doi:10.1109/tmi.2014.2363884
  3. 10.1002/gps.4179 · doi:10.1002/gps.4179
  4. 10.1118/1.4923891 · doi:10.1118/1.4923891
  5. 10.1007/s13534-014-0126-2 · doi:10.1007/s13534-014-0126-2
  6. Fleishman GM, 2015, Simultaneous Longitudinal Registration with Group‐Wise Similarity Prior, Inf Process Med Imaging, 24, 746
  7. Gutman B, 2015, A Riemannian Framework for Intrinsic Comparison of Closed Genus‐Zero Shapes, Inf Process Med Imaging, 9123, 205
  8. Zieselman AL, 2014, Computational genetics analysis of grey matter density in Alzheimer's disease, BioData Min, 7, 17, 10.1186/1756-0381-7-17 · doi:10.1186/1756-0381-7-17
  9. 10.1002/ana.24420 · doi:10.1002/ana.24420
  10. 10.1002/ana.24484 · doi:10.1002/ana.24484
  11. 10.1002/ana.24503 · doi:10.1002/ana.24503
  12. Hao X, 2014, Identifying genetic associations with MRI‐derived measures via tree‐guided sparse learning, Med Image Comput Comput Assist Interv, 17, 757
  13. Sheng J, 2014, Data synthesis and method evaluation for brain imaging genetics, Proc IEEE Int Symp Biomed Imaging, 2014, 1202
  14. 10.1002/gepi.21778 · doi:10.1002/gepi.21778
  15. Weiss TL, 2015, The role of visualization and 3‐D printing in biological data mining, BioData Min, 8, 22, 10.1186/s13040-015-0056-2 · doi:10.1186/s13040-015-0056-2
  16. Qi Z, 2014, Multivariate Analysis of structural MRI and PET (FDG and 18F‐AV‐45) for Alzheimer's disease and its prodromal stages, Conf Proc IEEE Eng Med Biol Soc, 2014, 1051
  17. MoradiE TohkaJ GaserC.Semi‐supervised learning in MCI‐to‐ad conversion prediction—When is unlabeled data useful?Pattern Recognition in Neuroimaging 2014 International Workshop on: IEEE;2014. p.1–4. · doi:10.1109/prni.2014.6858535
  18. Andrade de Oliveira A, 2015, Defining multivariate normative rules for healthy aging using neuroimaging and machine learning: an application to Alzheimer's disease, J Alzheimers Dis, 43, 201, 10.3233/JAD-140189 · doi:10.3233/jad-140189
  19. Ranjan P, 2014, Proposal of a new tractographic feature for analysis of white matter in Alzheimer diffusion mr images, Biomed Sci Instrum, 50, 322
  20. 10.1080/10543406.2014.971173 · doi:10.1080/10543406.2014.971173
  21. 10.1111/biom.12312 · doi:10.1111/biom.12312

Cited by

See all 315

Metadata

Authors
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Initiative, A. D. N.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2017-03-22
Volume
13
Issue
4
Pages
e1-e85
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2601368841
Cited by
315
References
467
FWCI
27.30
Type
journal article
Language
en
Open access
green
Funders
  • National Institute on Aging (P30AG010129, P30AG043097, U01AG024904, R01AG047827, P50 AG005681, P01 AG003991, R01AG048252, R01AG19771, P30AG10133, R44AG049540)
  • National Institute of Justice (2014‐R2‐CX‐0012)
  • National Institute of Neurological Disorders and Stroke (U54NS079202)
  • U.S. Department of Defense (W81XWH‐12‐2‐0012, W81XWH‐13‐1‐0259, W81XWH‐14‐1‐0462)
  • Office of Legacy Management (R01LM011360)
  • University of Pennsylvania (AG‐010124, NS‐053488)
  • Biogen
  • Siemens
  • AstraZeneca
  • Hôpitaux Universitaires de Genève
  • Eli Lilly and Company
  • University of California
  • Pfizer
  • Novartis
  • Tohoku University
  • U.S. Department of Veterans Affairs
  • Small Business Innovation Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. https://app.cochat.ai/papers/10.1016/j.jalz.2016.11.007
The paper
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Initiative, A. D. N. (2017). Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.11.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.